Tag Archives | targeted therapy

Three Biotech Stocks To Buy Now: ABBV,BLUE,GILD…Update-2

2/5/16 …11:20 AM Biotechs Can’t Hold Gains …Drop Back Near 52 Week Lows Hit Wednesday IBB $261  XBI $48 Update-2 At Close 2/4/16…Nice Rally But Off Earlier Highs-Very Stock Specific A nice snap-back rally with a lot of green screen across the board. A tradeable rally but we need follow-through next week. Your favorite stock […]

Continue Reading 0

Large Cap Biopharmaceuticals Winners and Losers 2015-16: Which Stocks Can Outperform the ETFs in 2016?… Part 1

Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a FED rate rise, with potentially less available equity funding, […]

Continue Reading 0

Biotech Stocks Snooze Through Today’s Rally Awaiting Earnings This Week: Large Cap Biopharmaceuticals… ABBV, AMGN, BIIB, BMY, CELG…Update-2

Earnings Updates-2… 1/29 Large Cap Biopharmaceuticals Valuation Models of Large Cap Biotech to be Updated Next Week IBB trying to bottom above $262 down 21.8% YTD Abbvie (ABBV) mixed Q4, maintains 2016 outlook of $4.90-$5.10;Q4 IMBRUVICA of $343M;Merck Hep-C competition coming. ABBV off 3.35%. Amgen (AMGN) beats raises 2016 forecast to $22-$22.5B, EPS $10.60-$11.00;2015 Revenues up […]

Continue Reading 0

Biotech Rally Underway After Hitting 52 Week Low Today…Update-After Close

Can the Reversal Hold? IBB Rockets up 2.75% to 285.49 after hitting 52 week low today at 268.52. XBI up 4.22% to $55.09. Notable movers: Large caps: ABBV, ALXN, AMGN, REGN; BIIB down 0.19%, GILD lagging up only 0.72%. Mid-caps all green: ALKS,CLVS,SGEN,VRTX. All Rayno Small caps recover: CRIS,GERN,GLYC etc. ————- Green Screen Across the […]

Continue Reading 0

Valuation Models for Large Cap Biopharma Stocks in a Bear Market

 Valuation Models for Large Cap Biopharma Stocks Can Robust Drug Pipelines Deliver Future EPS Growth? This is a follow-up of our post on 1/8/16 Large Cap Biopharmaceuticals which looks at valuation models and stock performance of selected companies after the J.P.Morgan Healthcare Conference and then again after 2015 earnings reports over the next few weeks. Which […]

Continue Reading 0

J.P.Morgan Conference #2: Red Screen Distracts Biotech Investors…Update

Green Screen Alert Market Update…IBB up 4% today erasing most of Wednesday’s Losses but we are still down 13.86% for the five day period. Nasdaq rallied 1.97%. Rayno Biopharma top winners: ABBV up 6.56%, ALXN up 5.93%, AMGN up 5.29%,BIIB up 4.98%, REGN up 4.25%,RXDX up 8.96%, SGEN up 2.26% and VRTX up 5.75%. Most […]

Continue Reading 0

J.P.Morgan Healthcare Conference #1: Investors Move into Life Science Stocks-Bouncing off the Bottom

J.P.Morgan Conference: Relief Rally in Life Science Stocks After Rough Start to 2016 Green screen day with improved macro and healthcare sector leading Who knew biotech stocks traded with energy? Over the next few days we will review themes and companies from presentations at the 34th Annual J.P.Morgan Healthcare Conference. Our initial focus will be […]

Continue Reading 0

Can Large Cap Biopharmaceutical Stocks Outperform in 2016?

 Large Cap Biopharmaceutical Stock Valuations After Correction We previously summarized the Rayno Mid and Small Cap Portfolios for 2015, a good year despite the correction. With this post we summarized selected Sales and Earnings metrics (Source finviz.com) of important large cap biotech stocks for the purpose of analysis after the J.P. Morgan Healthcare Conference and […]

Continue Reading 0

Biotech Bear Market Rally on Hold: Lackluster Tape for Week One 2016…Update-1

Update-1… 3P EST –Biotechs Sink Further XBI Down 5%, IBB down 2.34% Green stocks are hard to find: GILD, HOLX, REGN Biotech Bear Market: Lackluster Tape Says Wait Until Next Week For Market Direction Year-End Rally Fizzles in New Year Biotech stocks (IBB) are off 5% from year-end 2015 highs and up only 6.73% from […]

Continue Reading 0

Biotech Winners 2015: Rayno Mid Caps Were Up 29.6%

Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015  and the Mid-Caps also beat despite a big loss by Clovis Oncology after the FDA required more data on its lung cancer drug. The […]

Continue Reading 0

2015 Life Science Sector Review As Biopharma Rally Fades

Biopharma Rally On Hold This is not a good week for trading. Portfolio managers are re-jiggering positions so you may not see the trends correctly. Today there was much more red than green.Many biotech stocks started rallying off the bottom in October then again around December 11. There are many cross currents in the market […]

Continue Reading 0

Bear Market Biotech Rally Is Tradeable…Update-1

Update after close 12/16…IBB up 2.25%, XBI up 4.45% Rayno Life Science Big Movers Rayno Biopharma ABBV up 2.2%,ALKS up 8.12%, BIIB up 3.52%, ARRY up 20.63 %, CRIS up 6.27%, FCSC up 5%, GERN up 4.42%,RXDX up 2.92% and SGEN up 4.93%. Rayno Dx and Tools ABAX up 2.57%, CPHD up 4.87%,GHDX up 2.87% […]

Continue Reading 0

Healthcare Stocks Will be Under Fire in 2016; Biotech Rally Needs Help…Update-2

Tradeable Intermediate Bottom Today  12:36P… 12/15 GILD 102.8,IBB 331 Update at Close Update…Sunday 12/13/15…Grim Outlook…Risk Off The market sunk further Friday afternoon after 3p for a NASDAQ close at 4933 off 2.33% (up 4.17% YTD) for the day.Biotech ETFS were hit even harder with the IBB down 2.89% (up 5.45% YTD) and the XBI down […]

Continue Reading 0

Rayno Molecular Diagnostics and Tools Update: CPHD, HOLX, PACB

Dominant Trend is Precision Medicine and Molecular Medicine Lackluster revenue growth has tempered stock gains since Q3 earnings reports however the sector has always had good investment potential due to M&A and new products. Stocks are up from October lows. Our last update was in November and re-iterated the “Precision Medicine” trend which integrates targeted therapies […]

Continue Reading 0

Seasonal Biotech Rally on Track with Green Screen; RNA based therapeutics update (DMD)

Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants to go up another 8-10% before it hits resistance from the most recent big sell-off in mid-September. Today […]

Continue Reading 0